Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment

Alto met its enrollment goal with 83 patients across 13 US clinical sites

HanchorBio scores first FDA orphan drug tag for gastric cancer therapy

The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients

Irish medtech firm InVera Medical wins EU nod for breakthrough vein treatment device

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise

Biofrontera scores FDA filing acceptance for Ameluz PDT in skin cancer breakthrough

If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US

Dewpoint Therapeutics selects groundbreaking MYC development candidate

MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control

STADA & Bio-Thera bag European nod for Gotenfia

Amgen scores EU nod for UPLIZNA in rare autoimmune disease

The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses

Lyell Immunopharma launches groundbreaking Phase 3 CAR T-Cell trial for aggressive lymphoma

PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma

Centivax launches first human trial of universal flu vaccine